Experienced in Gliosarcoma

Dr. Michael R. Girvigian

Radiation Oncology
Kaiser Permanente
Los Angeles Medical Center
4950 W Sunset Boulevard, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Gliosarcoma
Kaiser Permanente
Los Angeles Medical Center
4950 W Sunset Boulevard, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Girvigian is a Radiation Oncologist in Los Angeles, California. Dr. Girvigian is rated as an Experienced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Meningioma, Arteriovenous Malformation, Tongue Cancer, and Angiosarcoma. Dr. Girvigian is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Gliosarcoma.

Specialties
Radiation Oncology
Licenses
Radiology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Los Angeles Medical Center
4950 W Sunset Boulevard, Los Angeles, CA 90027

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Radiation, Other
Study Phase: Phase 3
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
View 9 Less Clinical Trials

10 Total Publications

Impact of Fractionation Regimen on Local Control Following Frameless Linear Accelerator-Based Image-Guided Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma.
Impact of Fractionation Regimen on Local Control Following Frameless Linear Accelerator-Based Image-Guided Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma.
Journal: World neurosurgery
Published: May 26, 2024
Similar Doctors
Distinguished in Gliosarcoma
Dr. Tania B. Kaprealian
Radiation Oncology
Distinguished in Gliosarcoma
Dr. Tania B. Kaprealian
Radiation Oncology

The Regents Of The University Of California

200 Ucla Med Plaza, B265, 
Los Angeles, CA 
 (9.6 miles away)
310-825-9304
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tania Kaprealian is a Radiation Oncologist in Los Angeles, California. Dr. Kaprealian is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Meningioma, Schwannoma, Radiation Induced Meningioma, Acoustic Neuroma, and Thalamotomy.

Distinguished in Gliosarcoma
Dr. Peter V. Chen
Radiation Oncology
Distinguished in Gliosarcoma
Dr. Peter V. Chen
Radiation Oncology

Newport Coast Radiation Oncology Medical Group Inc

16105 Sand Canyon Ave, Suite 150, 
Irvine, CA 
 (43.9 miles away)
949-557-0210
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Chen is a Radiation Oncologist in Irvine, California. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Metastatic Pleural Tumor, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT).

Distinguished in Gliosarcoma
Dr. Amin J. Mirhadi
Radiation Oncology
Distinguished in Gliosarcoma
Dr. Amin J. Mirhadi
Radiation Oncology

Cedars-Sinai Medical Care Foundation

8635 W 3rd St, Suite 465w, 
Los Angeles, CA 
 (6.1 miles away)
310-423-0674
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amin Mirhadi is a Radiation Oncologist in Los Angeles, California. Dr. Mirhadi is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Lung Cancer, Posterior Fossa Tumor, Pleuropulmonary Blastoma, and Angiosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Girvigian's expertise for a condition
ConditionClose
        View All 43 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile